119 related articles for article (PubMed ID: 37915230)
1. Association of temozolomide with progressive multifocal leukoencephalopathy: a disproportionality analysis integrated with network pharmacology.
Bhati V; Kumar A; Lather V; Sharma R; Pandita D
Expert Opin Drug Saf; 2024 May; 23(5):649-658. PubMed ID: 37915230
[TBL] [Abstract][Full Text] [Related]
2. Drug-Induced Progressive Multifocal Leukoencephalopathy: A Comprehensive Analysis of the WHO Adverse Drug Reaction Database.
Melis M; Biagi C; Småbrekke L; Nonino F; Buccellato E; Donati M; Vaccheri A; Motola D
CNS Drugs; 2015; 29(10):879-91. PubMed ID: 26507833
[TBL] [Abstract][Full Text] [Related]
3. Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS).
Schmedt N; Andersohn F; Garbe E
Pharmacoepidemiol Drug Saf; 2012 Nov; 21(11):1216-20. PubMed ID: 22821419
[TBL] [Abstract][Full Text] [Related]
4. Progressive multifocal leukoencephalopathy in a patient with multiple myeloma: a case report and analysis of the FDA adverse event reporting system.
Jonasson E; Antulov R; Trøllund Pedersen P; Sejbæk T
Front Neurol; 2023; 14():1098930. PubMed ID: 37213905
[TBL] [Abstract][Full Text] [Related]
5. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system.
Raisch DW; Rafi JA; Chen C; Bennett CL
Expert Opin Drug Saf; 2016 Aug; 15(8):1003-11. PubMed ID: 27268272
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced hypoglycemia: a disproportionality analysis of the FAERS database.
Li J; Wang Y; Yang X; Zhu H; Jiang Z
Expert Opin Drug Saf; 2023 Nov; ():1-7. PubMed ID: 37909653
[TBL] [Abstract][Full Text] [Related]
7. Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database.
Nair HP; Kulkarni AR; Eswaran M; Subeesh V
Arab J Gastroenterol; 2023 Feb; 24(1):1-4. PubMed ID: 36725376
[TBL] [Abstract][Full Text] [Related]
8. Identification of Novel Signals Associated with US-FDA Approved Drugs (2013) Using Disproportionality Analysis.
Raghuvanshi S; Rahman MA; Posa MK; Kumar A
Curr Drug Saf; 2023 Nov; ():. PubMed ID: 37990902
[TBL] [Abstract][Full Text] [Related]
9. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies.
Molloy ES; Calabrese LH
Arthritis Rheum; 2012 Sep; 64(9):3043-51. PubMed ID: 22422012
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
Tomar VS; Patil V; Somasundaram K
Cell Biol Toxicol; 2020 Jun; 36(3):273-278. PubMed ID: 31758290
[TBL] [Abstract][Full Text] [Related]
11. Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS).
Mytheen S; Varghese A; Joy J; Shaji A; Tom AA
Expert Opin Drug Saf; 2023; 22(10):985-994. PubMed ID: 37294921
[TBL] [Abstract][Full Text] [Related]
12. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition.
Zhang WB; Wang Z; Shu F; Jin YH; Liu HY; Wang QJ; Yang Y
J Biol Chem; 2010 Dec; 285(52):40461-71. PubMed ID: 20880848
[TBL] [Abstract][Full Text] [Related]
13. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients.
Kothary N; Diak IL; Brinker A; Bezabeh S; Avigan M; Dal Pan G
J Am Acad Dermatol; 2011 Sep; 65(3):546-551. PubMed ID: 21514689
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system.
Wu Z; Zhou P; He N; Zhai S
Front Cardiovasc Med; 2022; 9():966331. PubMed ID: 36352852
[TBL] [Abstract][Full Text] [Related]
15. Network pharmacology-based strategy to investigate pharmacological mechanisms of Tinospora sinensis for treatment of Alzheimer's disease.
Zhou F; He K; Guan Y; Yang X; Chen Y; Sun M; Qiu X; Yan F; Huang H; Yao L; Liu B; Huang L
J Ethnopharmacol; 2020 Sep; 259():112940. PubMed ID: 32389853
[TBL] [Abstract][Full Text] [Related]
16. MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway.
Xu P; Zhang G; Hou S; Sha LG
Biomed Pharmacother; 2018 Oct; 106():1419-1427. PubMed ID: 30119215
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of JNK potentiates temozolomide-induced cytotoxicity in U87MG glioblastoma cells via suppression of Akt phosphorylation.
Vo VA; Lee JW; Lee HJ; Chun W; Lim SY; Kim SS
Anticancer Res; 2014 Oct; 34(10):5509-15. PubMed ID: 25275048
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells.
De Salvo M; Maresca G; D'agnano I; Marchese R; Stigliano A; Gagliassi R; Brunetti E; Raza GH; De Paula U; Bucci B
Int J Radiat Biol; 2011 May; 87(5):518-33. PubMed ID: 21405945
[TBL] [Abstract][Full Text] [Related]
19. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells.
Harder BG; Peng S; Sereduk CP; Sodoma AM; Kitange GJ; Loftus JC; Sarkaria JN; Tran NL
Mol Med; 2019 Nov; 25(1):49. PubMed ID: 31726966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
